MBRX - Moleculin Biotech Inc. (MBRX) Q4 2023 Earnings Call Transcript
2024-03-25 11:25:19 ET
Moleculin Biotech, Inc. (MBRX)
Q4 2023 Earnings Conference Call
March 25, 2024, 08:30 AM ET
Company Participants
Jenene Thomas - IR
Walter Klemp - Chairman and CEO
Paul Waymack - Senior CMO
Jonathan Foster - EVP and CFO
Conference Call Participants
Jonathan Aschoff - ROTH MKM
Vernon Bernardino - H.C. Wainwright
Presentation
Operator
Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded.
I'd now turn the conference over to Jenene Thomas, Investor Relations. Thank you. You may begin.
Jenene Thomas
Thank you, Gerald. Good morning, and welcome everyone. At this time, I would like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Moleculin's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports, Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully.
Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy or completeness of or that any independent source of verified any information obtained from third party source. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change....
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript